J
Jiang F. Zhong
Researcher at University of Southern California
Publications - 78
Citations - 2127
Jiang F. Zhong is an academic researcher from University of Southern California. The author has contributed to research in topics: Stem cell & Gene. The author has an hindex of 20, co-authored 66 publications receiving 1481 citations. Previous affiliations of Jiang F. Zhong include California Institute of Technology & Third Military Medical University.
Papers
More filters
Journal ArticleDOI
Engineering CAR-T cells.
TL;DR: The structure and evolution of chimeric antigen receptors are discussed, and the tools used for production of CAR-T cells are reported on, to address the challenges posed by the technology.
Journal ArticleDOI
A microfluidic processor for gene expression profiling of single human embryonic stem cells
Jiang F. Zhong,Jiang F. Zhong,Yan Chen,Joshua S. Marcus,Axel Scherer,Stephen R. Quake,Clive R. Taylor,Leslie P. Weiner +7 more
TL;DR: A microfluidic approach is reported that can extract total mRNA from individual single-cells and synthesize cDNA on the same device with high mRNA-to-cDNA efficiency, which makes large-scale single-cell gene expression profiling possible.
Journal ArticleDOI
Recent advances in CAR-T cell engineering
Ruihao Huang,Xiaoping Li,Yundi He,Wen Zhu,Lei Gao,Yao Liu,Li Gao,Qin Wen,Jiang F. Zhong,Cheng Zhang,Xi Zhang +10 more
TL;DR: The recent transformations in the ectodomain, transmembrane domain, and endodomains of the CAR structure are summarized, which, together with innovative manufacturing technology and improved cell sources, improve the prospects for the future development of CAR-T cell therapy.
Journal ArticleDOI
Pulsed laser triggered high speed microfluidic fluorescence activated cell sorter
Ting-Hsiang Wu,Yue Chen,Sung-Yong Park,Jason S. Hong,Tara TeSlaa,Jiang F. Zhong,Dino Di Carlo,Michael A. Teitell,Pei-Yu Chiou +8 more
TL;DR: A high speed and high purity pulsed laser triggered fluorescence activated cell sorter (PLACS) with a sorting throughput up to 20,000 mammalian cells/s with 37% sorting purity, 90% cell viability in enrichment mode, and >;90% purity in high purity mode at 1,500 Cells/s or 3,000 beads/s.
Journal ArticleDOI
CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion.
Xuanmao Jiao,Marco A. Velasco-Velázquez,Min Wang,Zhiping Li,Hallgeir Rui,Amy R. Peck,James E. Korkola,Xuelian Chen,Shaohua Xu,James B. DuHadaway,Sandra L. Guerrero-Rodríguez,Sankar Addya,Daniela Sicoli,Zhaomei Mu,Gang Zhang,Andres Stucky,Xi Zhang,Massimo Cristofanilli,Alessandro Fatatis,Joe W. Gray,Jiang F. Zhong,George C. Prendergast,Richard G. Pestell +22 more
TL;DR: This study offers a preclinical rationale to reposition CCR5 inhibitors to improve the treatment of breast cancer, based on their ability to enhance the tumor-specific activities of DNA-damaging chemotherapies administered in that disease.